Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acetaminophen + propoxyphene napsylate is an oral combination analgesic drug comprised of acetaminophen, a non-opioid analgesic and antipyretic, and propoxyphene napsylate, a mild opioid (narcotic) analgesic structurally related to methadone. Propoxyphene napsylate is the napsylate salt of dextropropoxyphene, introduced for oral dosage stability and lower water solubility. **Mechanism of action:** - Acetaminophen acts as an analgesic and antipyretic, exerting its antipyretic effect by inhibiting prostaglandin synthesis in the hypothalamic heat-regulating center. - Propoxyphene (dextropropoxyphene) is a centrally-acting opioid receptor agonist providing mild analgesic activity, with additional local anesthetic and antiarrhythmic (sodium channel-blocking) effects at higher doses or with metabolite (norpropoxyphene) accumulation. The combination provides greater analgesia than either agent alone. The product has been discontinued or withdrawn in the US and many other markets due to safety concerns, primarily cardiac toxicity and risk of fatal overdose[4][5][1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetaminophen + propoxyphene napsylate.